Cytokinetics confronted various difficulties in 2023. The FDA wouldn’t endorse its possible treatment for cardiovascular breakdown, and Cytokinetics rejected testing a trial drug for amyotrophic horizontal sclerosis, or ALS. The last option showed no effect in a review declared a month ago.
However, following the HCM results on December 27, CYTK stock has risen 105% as of Friday’s close after falling precipitously from late September to the end of the year.
Shares currently have an ideal IBD Computerized Relative Strength Rating of 99, which places their year execution in the main 1% of all stocks in any case industry bunch.